<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35358499</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1090-2430</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>353</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Experimental neurology</Title>
          <ISOAbbreviation>Exp Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mirtazapine treatment in a young female mouse model of Rett syndrome identifies time windows for the rescue of early phenotypes.</ArticleTitle>
        <Pagination>
          <StartPage>114056</StartPage>
          <MedlinePgn>114056</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.expneurol.2022.114056</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0014-4886(22)00081-4</ELocationID>
        <Abstract>
          <AbstractText>Rett Syndrome (RTT) is a rare X-linked neurodevelopmental disorder, mainly caused by mutations in the MECP2 gene. Reduction in monoamine levels in RTT patients and mouse models suggested the possibility to rescue clinical phenotypes through antidepressants. Accordingly, we tested mirtazapine (MTZ), a noradrenergic and specific-serotonergic tetracyclic antidepressant (NaSSA). In previous studies, we showed high tolerability and significant positive effects of MTZ in male Mecp2<sup>1m1.1Bird</sup>-knock-out mice, adult female Mecp2<sup>tm1.1Bird</sup>-heterozygous (Mecp2<sup>+/-</sup>) mice, and adult female RTT patients. However, it remained to explore MTZ efficacy in female Mecp2<sup>+/-</sup> mice at young ages. As RTT-like phenotypes in young Mecp2<sup>+/-</sup> mice have been less investigated, we carried out a behavioural characterization to analyze Mecp2<sup>+/-</sup> mice in "early adolescence" (6 weeks) and "young adulthood" (11 weeks) and identified several progressive phenotypes. Then, we evaluated the effects of either a 15- or a 30-day MTZ treatment on body weight and impaired motor behaviours in 11-week-old Mecp2<sup>+/-</sup> mice. Finally, since defective cortical development is a hallmark of RTT, we performed a histological study on the maturation of perineuronal nets (PNNs) and parvalbuminergic (PV) neurons in the primary motor cortex. The 30-day MTZ treatment was more effective than the shorter 15-day treatment, leading to the significant rescue of body weight, hindlimb clasping and motor learning in the accelerating rotarod test. Behavioural improvement was associated with normalized PV immunoreactivity levels and PNN thickness. These results support the use of MTZ as a new potential treatment for adolescent girls affected by RTT and suggest a possible mechanism of action.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Flores Gutiérrez</LastName>
            <ForeName>Javier</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Natali</LastName>
            <ForeName>Giulia</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giorgi</LastName>
            <ForeName>Jacopo</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Leonibus</LastName>
            <ForeName>Elvira</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy; Institute of Biochemistry and Cellular Biology (IBBC), National Research Council, Monterotondo, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tongiorgi</LastName>
            <ForeName>Enrico</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Life Sciences, University of Trieste, 34127 Trieste, Italy. Electronic address: tongi@units.it.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Exp Neurol</MedlineTA>
        <NlmUniqueID>0370712</NlmUniqueID>
        <ISSNLinking>0014-4886</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051783">Methyl-CpG-Binding Protein 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>A051Q2099Q</RegistryNumber>
          <NameOfSubstance UI="D000078785">Mirtazapine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051783" MajorTopicYN="N">Methyl-CpG-Binding Protein 2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078785" MajorTopicYN="N">Mirtazapine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015518" MajorTopicYN="Y">Rett Syndrome</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Antidepressants</Keyword>
        <Keyword MajorTopicYN="Y">GABAergic neurons</Keyword>
        <Keyword MajorTopicYN="Y">MECP2</Keyword>
        <Keyword MajorTopicYN="Y">Neuronal development</Keyword>
        <Keyword MajorTopicYN="Y">Parvalbuminergic neurons</Keyword>
        <Keyword MajorTopicYN="Y">Perineuronal nets</Keyword>
        <Keyword MajorTopicYN="Y">Rett syndrome</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>20</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35358499</ArticleId>
        <ArticleId IdType="doi">10.1016/j.expneurol.2022.114056</ArticleId>
        <ArticleId IdType="pii">S0014-4886(22)00081-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35358499</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1090-2430</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>353</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Experimental neurology</Title>
          <ISOAbbreviation>Exp Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mirtazapine treatment in a young female mouse model of Rett syndrome identifies time windows for the rescue of early phenotypes.</ArticleTitle>
        <Pagination>
          <StartPage>114056</StartPage>
          <MedlinePgn>114056</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.expneurol.2022.114056</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0014-4886(22)00081-4</ELocationID>
        <Abstract>
          <AbstractText>Rett Syndrome (RTT) is a rare X-linked neurodevelopmental disorder, mainly caused by mutations in the MECP2 gene. Reduction in monoamine levels in RTT patients and mouse models suggested the possibility to rescue clinical phenotypes through antidepressants. Accordingly, we tested mirtazapine (MTZ), a noradrenergic and specific-serotonergic tetracyclic antidepressant (NaSSA). In previous studies, we showed high tolerability and significant positive effects of MTZ in male Mecp2<sup>1m1.1Bird</sup>-knock-out mice, adult female Mecp2<sup>tm1.1Bird</sup>-heterozygous (Mecp2<sup>+/-</sup>) mice, and adult female RTT patients. However, it remained to explore MTZ efficacy in female Mecp2<sup>+/-</sup> mice at young ages. As RTT-like phenotypes in young Mecp2<sup>+/-</sup> mice have been less investigated, we carried out a behavioural characterization to analyze Mecp2<sup>+/-</sup> mice in "early adolescence" (6 weeks) and "young adulthood" (11 weeks) and identified several progressive phenotypes. Then, we evaluated the effects of either a 15- or a 30-day MTZ treatment on body weight and impaired motor behaviours in 11-week-old Mecp2<sup>+/-</sup> mice. Finally, since defective cortical development is a hallmark of RTT, we performed a histological study on the maturation of perineuronal nets (PNNs) and parvalbuminergic (PV) neurons in the primary motor cortex. The 30-day MTZ treatment was more effective than the shorter 15-day treatment, leading to the significant rescue of body weight, hindlimb clasping and motor learning in the accelerating rotarod test. Behavioural improvement was associated with normalized PV immunoreactivity levels and PNN thickness. These results support the use of MTZ as a new potential treatment for adolescent girls affected by RTT and suggest a possible mechanism of action.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Flores Gutiérrez</LastName>
            <ForeName>Javier</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Natali</LastName>
            <ForeName>Giulia</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giorgi</LastName>
            <ForeName>Jacopo</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Leonibus</LastName>
            <ForeName>Elvira</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy; Institute of Biochemistry and Cellular Biology (IBBC), National Research Council, Monterotondo, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tongiorgi</LastName>
            <ForeName>Enrico</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Life Sciences, University of Trieste, 34127 Trieste, Italy. Electronic address: tongi@units.it.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Exp Neurol</MedlineTA>
        <NlmUniqueID>0370712</NlmUniqueID>
        <ISSNLinking>0014-4886</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051783">Methyl-CpG-Binding Protein 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>A051Q2099Q</RegistryNumber>
          <NameOfSubstance UI="D000078785">Mirtazapine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051783" MajorTopicYN="N">Methyl-CpG-Binding Protein 2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078785" MajorTopicYN="N">Mirtazapine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015518" MajorTopicYN="Y">Rett Syndrome</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Antidepressants</Keyword>
        <Keyword MajorTopicYN="Y">GABAergic neurons</Keyword>
        <Keyword MajorTopicYN="Y">MECP2</Keyword>
        <Keyword MajorTopicYN="Y">Neuronal development</Keyword>
        <Keyword MajorTopicYN="Y">Parvalbuminergic neurons</Keyword>
        <Keyword MajorTopicYN="Y">Perineuronal nets</Keyword>
        <Keyword MajorTopicYN="Y">Rett syndrome</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>20</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35358499</ArticleId>
        <ArticleId IdType="doi">10.1016/j.expneurol.2022.114056</ArticleId>
        <ArticleId IdType="pii">S0014-4886(22)00081-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
